PeptidePreclinical
Survodutide
Also known as: BI 456906
Dual GLP-1/Glucagon Receptor Agonist | Weight Loss & Diabetes
Overview
Investigational dual receptor agonist targeting metabolic disease through balanced GLP-1R and GCGR activation. Phase 2/3 clinical trials demonstrate superior weight loss and MASH treatment efficacy.
Key benefits
- Superior weight loss vs monotherapy (14.9% at 46 weeks)
- Once-weekly convenient dosing
- Proven efficacy in obesity, MASH, and Type 2 diabetes
- 62% MASH improvement in clinical trials
Mechanism of action
Dual agonism: GLP-1R reduces appetite and slows gastric emptying; GCGR increases energy expenditure and hepatic fat oxidation. EC50 0.52nM GCGR, 0.33nM GLP-1R.
Molecular data
- Type
- Peptide with fatty acid acylation
- Half-life
- Approximately 6 days (109-115 hours)
Sequence
29-amino acid peptide
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Metabolic
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 0.6mg titrated over 24 weeks | Once weekly with 4-week intervals | — |
| — | 3.6-6.0mg | Once weekly | — |
| — | 2.4-4.8mg | Once weekly | — |
| — | 0.3-2.7mg | Once weekly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea (40-66%)
- Diarrhea (25-49%)
- Vomiting (15-41%)
- Slight heart rate increase (mean 2-5 bpm)
Contraindications
- Not recommended in pregnancy or breastfeeding
- Use contraception during treatment
Monitoring
- Monitor blood glucose if on diabetes medications
- No dose adjustment needed for hepatic impairment (including cirrhosis)
- Monitor heart rate in patients with cardiac conditions